Bisoprolol fumarate

SOURCE: eMC UK SPC, productName 'Bisoprolol 1.25 mg Orodispersible Tablets' (https://www.medicines.org.uk/emc/product/102393/smpc), §4.2. TITRATION PHASE, VERBATIM: 1.25 mg once daily for 1 week, if well tolerated increase to 2.5 mg once daily for a further week, if well tolerated increase to 3.75 mg once daily for a further week, if well tolerated increase to 5 mg once daily for the 4 following weeks, if well tolerated increase to 7.5 mg once daily for the 4 following weeks, if well tolerated increase to 10 mg once daily for the maintenance therapy. The maximum recommended dose is 10 mg once daily. Close monitoring of vital signs (heart rate, blood pressure) and of symptoms of worsening heart failure is recommended during the titration phase; symptoms may already occur within the first day after initiating therapy. INDICATION SCOPE CAVEAT — READ BEFORE USE: this SPC's §4.2 covers stable chronic heart failure ONLY (as an adjunct to an ACE inhibitor or ARB, a diuretic and, when appropriate, cardiac glycosides), with the patient stable and without acute failure when bisoprolol is initiated, and it is recommended that the treating physician be experienced in the management of chronic heart failure. It contains NO UK posology for hypertension, angina or rate control in atrial fibrillation — those regimens are not asserted here and must be sourced from the relevant UK SPC. US LABELLING (openFDA cross-check only, Solco Healthcare US, DailyMed 2023-06-26 — a HYPERTENSION regimen, NOT the UK heart-failure regimen above, and its 20 mg ceiling does not apply to it): 'The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose... If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily', with an initial daily dose of 2.5 mg in hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min). TREATMENT MODIFICATION: if the maximum recommended dose is not well tolerated, gradual dose reduction may be considered; in case of transient worsening of heart failure, hypotension or bradycardia, reconsider the dosage of the concomitant medication and consider temporarily lowering the bisoprolol dose or discontinuing it, reintroducing or uptitrating once the patient is stable again. WITHDRAWAL: if discontinuation is considered, gradual dose decrease is recommended, since abrupt withdrawal may lead to acute deterioration of the patient's condition; especially in ischaemic heart disease cessation must not be abrupt unless clearly indicated. Treatment is generally long-term. HEPATIC/RENAL: there is no information on the pharmacokinetics of bisoprolol in chronic heart failure patients with impaired hepatic or renal function, so uptitration should be made with additional caution. OLDER PEOPLE: no dosage adjustment is required. PAEDIATRIC: 'There is no paediatric experience with bisoprolol, therefore its use cannot be recommended in paediatric patients' — hence paedDose is null. SURGERY (§4.4): maintenance beta-blockade is currently recommended to be continued peri-operatively, and the anaesthetist must be aware of the beta-blockade; if withdrawal before surgery is thought necessary it should be gradual and completed about 48 hours before anaesthesia. SOURCE NOTE: eMC §4.5 was not captured in this bundle (the §4.4 text is truncated at the source-fetch limit) — the interactions listed below are taken from the retrieved part of §4.4; review the full §4.5 in the SPC.